Plain-English translation of NCT07373639 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a long-term follow-up study for patients who received BEAM-101, a gene-editing treatment designed to help people with sickle cell disease and similar blood disorders. Researchers want to track how you're doing over many years to make sure the treatment remains safe and continues to help your body make healthier blood cells.
Gene-editing treatments for blood disorders are relatively new, and doctors need to understand how they work over the long term. This study helps answer important questions about whether the benefits last, whether any new side effects appear over time, and how this medication affects quality of life years after treatment.
You likely qualify if…
You likely don't qualify if…
You'll have check-in visits once a year for the first 5 years, with phone or virtual check-ins every 6 months in between. After Year 5, visits shift to every 3 years, with annual phone check-ins, continuing through Year 15. During these visits, doctors will do blood tests and ask about your health to monitor how well the treatment is working and watch for any long-term effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States